Press Releases

Read Regulatory and non-regulatory press releases

  • All
  • Non-Regulatory
  • Regulatory
Regulatory

Oncology Venture provides financial details regarding its recent acquisition of additional ownership in dovitinib

Regulatory

Oncology Venture increases its ownership in dovitinib

Non-Regulatory

OV’s method can predict if neoadjuvant treatment with doxorubicin in breast cancer will be successful, data published in ASCO journal

Regulatory

Oncology Venture receives response from the FDA to the IND-application and proposed pivotal study for LiPlaCis

Regulatory

Oncology Venture publishes Q1 report for 2019

Regulatory

Oncology Venture – New date for registration of current rights issue

Regulatory

Oncology Venture has successfully executed capital increase with a value in excess of SEK 80m.

Regulatory

Oncology Venture management participates in current rights issue

Regulatory

Oncology Venture prolongs subscription period

Regulatory

Oncology Venture provides news on its clinical development projects dovitinib, 2X‑121 and LiPlaCis

Non-Regulatory

Oncology Venture Investor Events in Q2 2019 – new event

Non-Regulatory

Oncology Venture Investor Events in Q2 2019

Non-Regulatory

Editorial in Pharmagenomics explains how DRP® can guide the treatment for breast cancer

Regulatory

Correction: Oncology Venture today publishes a supplement to the prospectus published April 5, 2019 – without MAR plate

Regulatory

Oncology Venture today publishes a supplement to the prospectus published April 5, 2019

Non-Regulatory

Oncology Venture invites to a webcast April 8 at 16:30

Regulatory

Oncology Venture hereby publishes a prospectus regarding the rights issue starting on April 17, 2019

Regulatory

The Board of Oncology Venture resolves to conduct a rights issue of new shares

Regulatory

Minutes of Ordinary General Meeting

Regulatory

Oncology Venture obtains option to in-license the European rights to the FDA approved ixabepilone